Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Stomach Cancer Clinical Trials

100 recruiting trials for Stomach Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
100
Total Trials
100
Recruiting Now
6
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT05366881

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer...

Sponsor: Adela, IncEnrolling: 700017 locations
RECRUITINGPhase 1NCT06821048

Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors

This is a phase I clinical study to evaluate the safety and tolerability of FAST targeted chimeric antigen receptor (CAR)-T cells (PTC13) in patients with carcinoembryonic antigen...

Sponsor: Weijia Fang, MDEnrolling: 181 location
RECRUITINGNCT07076979

Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric...

This prospective clinical observational study aims to construct a metabolite database specifically for gastric cancer patients using metabolomics technology. It seeks to develop...

Sponsor: Shanghai Minimally Invasive Surgery CenterEnrolling: 2501 location
RECRUITINGPhase 1 / Phase 2NCT03190941

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of...

Background: A new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person. This...

Sponsor: National Cancer Institute (NCI)Enrolling: 1101 location
RECRUITINGNCT06982768

How Epigenetic Changes in hMLH1 Connect Lab Research With Diagnosis in Gastric Cancer

DNA methylation is one of the key mechanisms that are thought to underlie the association between aging and cancer. Several methylation-based measures of biological aging have...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 2451 location
RECRUITINGNCT07056010

Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion...

This is a prospective, open-label, single-center, Phase II clinical trial. Thirty patients with HER2-negative gastric adenocarcinoma or gastroesophageal junction (GEJ) cancer,...

Sponsor: The First Affiliated Hospital with Nanjing Medical UniversityEnrolling: 301 location
RECRUITINGNCT05993234

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction...

Trastuzumab deruxtecan (T-DXD) as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive advanced gastric or gastroesophageal junction (GEJ)...

Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyEnrolling: 25720 locations
RECRUITINGPhase 2NCT06962137

Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer

This study examines whether adding the drug Zolbetuximab to an existing treatment (Paclitaxel and Ramucirumab) can improve patients' survival. The goal is to see if this...

Sponsor: Universitaire Ziekenhuizen KU LeuvenEnrolling: 1006 locations
RECRUITINGPhase 1 / Phase 2NCT04592211

Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer

Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus...

Sponsor: Yonsei UniversityEnrolling: 711 location
RECRUITINGNCT05108298

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology GroupEnrolling: 40020 locations
RECRUITINGPhase 2NCT07294664

PD1/TGFβ In Combination With EZH2 And Chemotherapy For First - Line Treatment Of Gastric Cancer

Immunotherapy combined with chemotherapy has become the standard first-line treatment regimen for gastric cancer. However, a subset of patients still fail to benefit or derive...

Sponsor: The First Affiliated Hospital of Zhengzhou UniversityEnrolling: 361 location
RECRUITINGPhase 2 / Phase 3NCT05699655

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann...

To evaluate the clinical efficacy and safety of Tislelizumab combined with apatinib mesylate, oxaliplatin plus S1 Vs oxaliplatin plus S1.

Sponsor: Fujian Cancer HospitalEnrolling: 1301 location
RECRUITINGNCT03463668

Evaluation of the Efficacy of Duodenal Prostheses Not Covered Over 6 Years

To assess the efficacy of duodenal prostheses for duodenal stenosis established for endoscopic pyloric or duodenal stenosis on dysphagia

Sponsor: Institut Paoli-CalmettesEnrolling: 2001 location
RECRUITINGNCT01048281

Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

Our research of the biology of upper gastrointestinal cancers involves the study of tissue samples and cells from biopsies of persons with gastric or esophageal cancer or blood...

Sponsor: Stanford UniversityEnrolling: 1001 location
RECRUITINGPhase 3NCT04787354

Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)

This study aims to compare the efficacy and safety of reduced adjuvant XELOX treatment (4 cycles of XELOX followed by 4 cycles of capecitabine alone) to standard adjuvant XELOX...

Sponsor: Hallym University Medical CenterEnrolling: 9761 location
RECRUITINGPhase 2NCT03935893

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in...

Sponsor: Udai KammulaEnrolling: 2401 location
RECRUITINGNCT06735105

Study on the Value of Three DWI Scanning Sequences in Staging of Gastric Cancer

Accurate staging is critical for effective gastric cancer treatment planning. Conventional DWI (C-DWI) has limitations in image quality due to magnetic field inhomogeneity, which...

Sponsor: Yunnan Cancer HospitalEnrolling: 1291 location
RECRUITINGPhase 1NCT05969041

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial...

Sponsor: Myeloid TherapeuticsEnrolling: 486 locations
RECRUITINGPhase 2NCT07194005

Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer

This study aims to evaluate the efficacy of disitamab vedotin in combination with sintilimab and SOX as conversion therapy in patients with initially unresectable locally advanced...

Sponsor: Fudan UniversityEnrolling: 301 location
RECRUITINGPhase 3NCT06177041

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative,...

Gastric/GEJ adenocarcinoma, which is one of the major leading causes of cancer-related deaths worldwide, is a global challenge to human health. However, standard chemotherapy has...

Sponsor: FutureGen Biopharmaceutical (Beijing) Co., LtdEnrolling: 4861 location
RECRUITINGNCT06639490

Efficacy of RUS GA Surgical Navigation for Robot-assisted Distal Gastrectomy in Gastric Cancer Patients

This investigator-initiated, randomized superiority clinical trial aims to demonstrate the clinical effectiveness of RUS GA Surgical Navigation, an endoscopic imaging treatment...

Sponsor: Yonsei UniversityEnrolling: 3301 location
RECRUITINGPhase 1 / Phase 2NCT06047379

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the...

Sponsor: Neonc Technologies, Inc.Enrolling: 1346 locations
RECRUITINGNCT06962293

Magnetic Guided Counetrtraction During Endoscopic Submucosal Dissection

Endoscopic submucosal dissection (ESD) is a technique that allows curative treatment of early gastrointestinal neoplasia with organ preservation. However, it is a technically...

Sponsor: Chinese University of Hong KongEnrolling: 201 location
RECRUITINGNCT05344339

Billroth-II Modified Versus Roux-en-Y After Distal Gastrectomy for Gastric Cancer

There are Billroth-I, Billroth-II, Billroth-II with Braun, and Roux-en-Y reconstruction after distal gastrectomy. Hypothesis: Billroth-II modified method is non-inferior to...

Sponsor: University Medical Center Ho Chi Minh City (UMC)Enrolling: 3201 location
RECRUITINGPhase 3NCT05226169

Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)

The main objective of this study is to evaluate the efficacy and safety of IV FCM(ferric carboxymaltose) in patients with AGC receiving palliative chemotherapy. This study will...

Sponsor: Asan Medical CenterEnrolling: 3301 location
RECRUITINGNCT05537129

Laparoscopic vs Open Total Gastrectomy for Gastric Cancer

The aim of the present study is to demonstrated the the safety and feasibility of laparoscopic total gastrectomy comparing with open total gastrectomy.

Sponsor: Fudan UniversityEnrolling: 6001 location
RECRUITINGPhase 2NCT05494060

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric...

This is an open label, randomized, phase Ⅱ, multi-cohort study to treat subjects with ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma. The patients will be...

Sponsor: The First Affiliated Hospital with Nanjing Medical UniversityEnrolling: 801 location
RECRUITINGNCT05205343

Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal...

To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 204 locations
RECRUITINGNCT07312760

Existential Distress in Advanced Cancer: Comparing a Short-term Psychodynamic Psychotherapy (ORPHYS) to Treatment as...

The psychological challenges faced by patients with incurable cancer and their caregivers include an uncertain future, fear of dying and uncontrollable suffering, grief, and...

Sponsor: Universitätsklinikum Hamburg-EppendorfEnrolling: 1603 locations
RECRUITINGPhase 1NCT06830031

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

This study is to investigate the safety and tolerability of C402-CD19-CAR treatment in subjects with relapsed or refractory large B-cell lymphoma and further determine the...

Sponsor: Shanghai Exuma Biotechnology Ltd.Enrolling: 181 location
RECRUITINGPhase 3NCT06755554

Investigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer

The study aims to evaluate the safety and benefits of using indocyanine green in lymph node dissection for gastric cancer surgery. The primary endpoint is the average number of...

Sponsor: Ukrainian Society of Clinical OncologyEnrolling: 1052 locations
RECRUITINGPhase 2NCT04114136

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE...

Sponsor: Dan ZandbergEnrolling: 721 location
RECRUITINGNCT06417892

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

To explore the efficacy and safety of fruquintinib and albumin-paclitaxel combined with or without PD-1 antibody in the second-line treatment of advanced gastric/gastroesophageal...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 601 location
RECRUITINGNCT06792149

Prediction of Drug Response in Gastric Cancer Based on 3D Bioprinting

The therapeutic regimens for adjuvant and neoadjuvant chemotherapy in gastric cancer (GC) predominantly hinge on clinical experience. Consequently, there is an imperative need for...

Sponsor: Peking Union Medical College HospitalEnrolling: 601 location
RECRUITINGPhase 2NCT06519591

Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the...

In this phase 2 study, we combined Cadonilimab, LM-302, and S-1 combined with intraperitoneal infusion of paclitaxel as regimen to treat gastric cancer patients with peritoneal...

Sponsor: Ruijin HospitalEnrolling: 401 location
RECRUITINGPhase 1NCT06253871

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with...

Sponsor: Iambic Therapeutics, IncEnrolling: 24320 locations
RECRUITINGNCT04221893

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic). Radiation...

Sponsor: University of California, San FranciscoEnrolling: 282 locations
RECRUITINGNCT07069842

The Construction of a Predictive Model for Gastric Cancer Immunotherapy Response Based on Tumor-Infiltrating...

Gastric cancer is one of the cancers with a high mortality rate globally, and its treatment outcomes urgently need to be improved. The emergence of immunotherapy has broken...

Sponsor: Changzhi People's Hospital Affiliated to Changzhi Medical CollegeEnrolling: 1701 location
RECRUITINGNCT06308510

Detection of Aneuploidy in Cell Free DNA to Improve the Sensitivity of Diagnostic Peritoneal Lavage in Gastric Cancer

Aneuploidy may be used as a more sensitive diagnostic tool to detect peritoneal metastasis compared to conventional cytology and imaging techniques. Our aim is to establish...

Sponsor: Erasmus Medical CenterEnrolling: 631 location
RECRUITINGPhase 2NCT06157996

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low...

This is a multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of intensive treatment with lenvatinib plus tislelizumab and CapeOX as first-line...

Sponsor: Nanfang Hospital, Southern Medical UniversityEnrolling: 921 location
RECRUITINGPhase 2NCT06760819

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in...

Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers...

Sponsor: BayerEnrolling: 11120 locations
RECRUITINGPhase 2NCT04550494

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

This phase II trial studies if talazoparib works in patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the...

Sponsor: National Cancer Institute (NCI)Enrolling: 364 locations
RECRUITINGNCT06495645

Miss Rate of Gastric Neoplasms Under Computer-aided Endoscopy

This prospective randomized trial compares AI-assisted upper gastrointestinal endoscopy with high definition upper gastrointestinal endoscopy in term of missed rate of gastric...

Sponsor: The University of Hong KongEnrolling: 10001 location
RECRUITINGNCT02139605

"Phase III Randomized Trial Comparing D2 vs D3 Lymphadenectomy With Gastric Cancer Following Neoadjuvant Chemotherapy

Stomach cancer is the second most common cause of cancer-related deaths in India. Curative surgery offers the only chance of improving survival in this cancer. In patients whose...

Sponsor: Tata Memorial CentreEnrolling: 4001 location
RECRUITINGNCT05349227

Comprehensive Outcomes for After Cancer Health

This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary...

Sponsor: Pack HealthEnrolling: 6257 locations
RECRUITINGPhase 1NCT05277766

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal...

Sponsor: University Hospital, GhentEnrolling: 451 location
RECRUITINGPhase 2NCT06711471

Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

For patients with metastatic gastric cancer, the efficacy of current standard treatments outlined in the guidelines is far from meeting the clinical demand. This study aims to...

Sponsor: LIN YANGEnrolling: 311 location
RECRUITINGPhase 3NCT01935778

Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric...

multicenter, open label, randomaized, phase III The role of post surgery adjuvant chemotherapy is becoming more and more important in AGC (advance gastric cancer). S-1 and...

Sponsor: Asan Medical CenterEnrolling: 2861 location
RECRUITINGPhase 1NCT05514717

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.

Sponsor: Mersana TherapeuticsEnrolling: 16214 locations
RECRUITINGNCT06033976

Endoscopic Submucosal Dissection Registry

This is a patient registry for all cases of pre-neoplastic or early neoplastic digestive tract lesions treated with curative intention by endoscopic submucosal dissection (ESD)...

Sponsor: Carol Davila University of Medicine and PharmacyEnrolling: 2001 location

Showing 50 of 100 trials.Search all Stomach Cancer trials

Frequently Asked Questions

There are currently 100 clinical trials for Stomach Cancer, with 100 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Stomach Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 6 Phase 3 trials for Stomach Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.